Clinical Trial Update: A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A [Phase 4]

View source ↗

Summary

Phase 4 retreatment trial evaluating elbasvir/grazoprevir plus sofosbuvir and ribavirin in chronic hepatitis C genotypes 1 and 4 patients who previously failed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sovaldi (Sofosbuvir)
• Zepatier (elbasvir/grazoprevir)

Snippet

Sponsor: Fundacion SEIMC-GESIDA | Conditions: HCV | Phase 4 | Status: WITHDRAWN